|
KMID : 0311120230640090531
|
|
Yonsei Medical Journal
2023 Volume.64 No. 9 p.531 ~ p.540
|
|
|
Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy
|
|
Jung Seung-Hyun
Lee Choong-Kun
Kwon Woo-Sun
Yun Su-Jin
Jung Min-Kyu
Kim Hyo-Song
Chung Hyun-Cheol
Chung Yeun-Jun
Rha Sun-Young
|
|
|
Abstract
|
|
|
Purpose: For precision medicine, exploration and monitoring of molecular biomarkers are essential. However, in advanced gas tric cancer (GC) with visceral lesions, an invasive procedure cannot be performed repeatedly for the follow-up of molecular bio markers.
Materials and Methods: To verify the clinical implication of serial liquid biopsies targeting circulating tumor DNA (ctDNA) on treatment response, we conducted targeted deep sequencing for serially collected ctDNA of 15 HER2-positive metastatic GC pa tients treated with anti-PD-1 inhibitor in combination with standard systemic treatment.
Results: In the baseline ctDNAs, 14 patients (93%) harbored more than one genetic alteration. A number of mutations in well known cancer-related genes, such as KRAS and PIK3CA, were identified. Copy number alterations were identified in eight GCs (53.3%), and amplification of the ERBB2 gene (6/15, 40.0%) was the most recurrent. When we calculated the mean variant allele frequency (VAF) of mutations in each ctDNA as the molecular tumor burden index (mTBI), the mTBI trend was largely consistent with the VAF profiles in both responder and non-responder groups. Notably, in the longitudinal analysis of ctDNA, mTBI provided 2?42 weeks (mean 13.4 weeks) lead time in the detection of disease progression compared to conventional follow-up with CT im aging.
Conclusion: Our data indicate that the serial genetic alteration profiling of ctDNA is feasible to predict treatment response in HER2-positive GC patients in a minimally invasive manner. Practically, ctDNA profiles are useful not only for the molecular diag nosis of GC but also for the selection of GC patients with poor prognosis for systemic treatment (ClinicalTrials.gov identifier: NCT02901301).
|
|
|
KEYWORD
|
|
|
Gastric cancer, liquid biopsy, circulating tumor DNA, immune checkpoint inhibitor, molecular tumor burden index
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|
|